Navigation Links
Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
Date:9/30/2008

which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, CEA and MCSP, respectively, are in preclinical development. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the completion of the financing described herein, the efficacy, safety and intended utilization of our product candidates, the development of our BiTE antibody technology, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, and our plans regarding future presentations of clinical data. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results fro
'/>"/>

SOURCE Micromet, Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
2. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
3. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
4. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
5. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
6. Micromet to Present at Two Upcoming Investor Conferences
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
9. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
10. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
11. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... August 31, 2014 2014 ... is a professional and in-depth research report ... basic Polyacrylamide information, including Polyacrylamide definition, classification, ... as industry overview. This research covers the ... well as global industry analysis covering macroeconomic ...
(Date:8/29/2014)... Electronic circuits are based on electrons, but one of ... photonic circuits, i.e. circuits based on light (photons) instead ... to create a stream of single photons and control ... sorts of attempts to achieve this control, but now ... creating a steady stream of photons emitted one at ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo ... ICOTF), today reported financial results for the six ... otherwise, are expressed in Canadian dollars and presented ... Second Quarter 2014 Highlights , Announced ... acuity (VA) primary endpoint for subjects enrolled in ...
(Date:8/29/2014)... August 29, 2014 A major challenge ... biotech start-up dense realm of Boston-Cambridge, is gaining visibility ... investors. James Sherley, the Director of Boston’s Adult Stem ... local and national visibility of his company an important ... , In addition to a social media marketing ...
Breaking Biology Technology:International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Breakthrough in light sources for new quantum technology 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4
... May 16, 2011 Palatin Technologies, Inc. (NYSE Amex: ... dysfunction indications and PL-3994 for acute asthma and other indications, ... 2011. Recent Highlights ... Administration (FDA), Palatin submitted a revised protocol to the FDA ...
... May 13, 2011 InterMune, Inc. (Nasdaq: ... results from two Phase 3 trials demonstrating that treatment ... associated with favorable effects on lung function, 6-minute walk ... mild to moderate idiopathic pulmonary fibrosis (IPF).  IPF is ...
... Novavax, Inc. (Nasdaq: NVAX ) a clinical-stage ... of Novavax, will be presenting at the NOBLE FINANCIAL 7th ... The Hard Rock Hotel, Hollywood, FL.  A live audio-only webcast ... website at www.novavax.com under Investors/Events. ...
Cached Biology Technology:Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 2Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 3Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 4Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 5Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 6Pirfenidone Phase 3 Results Published Today in The Lancet 2Pirfenidone Phase 3 Results Published Today in The Lancet 3Pirfenidone Phase 3 Results Published Today in The Lancet 4Pirfenidone Phase 3 Results Published Today in The Lancet 5Pirfenidone Phase 3 Results Published Today in The Lancet 6
(Date:8/29/2014)... researchers explored the type and number of connections in ... plays on robustness in a study published in ... found that the assortativity signature contributes to a network,s ... that varying the out-out assortativity of TFN models has ... the other three types of assortativity," said Dov A. ...
(Date:8/29/2014)... German . ... considered the oldest form of communication. Acting as messenger ... the sexual attraction between males and females. Fish rely ... reproductive behavior in males and females. Scientists at the ... in Faro, Portugal, and at the Max Planck Institute ...
(Date:8/29/2014)... In a cell,s nucleus, chromosomal DNA is tightly ... amalgam biologists call chromatin. Until about two decades ... the mere packing material around which the glamorous ... developed a greater appreciation for how DNA/histone interactions ... multiple research institutions studying the sequence of the ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Ready for mating at the right time 2Ready for mating at the right time 3'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3
... Elastin-like polypeptides (ELPs) cause plants to store GM proteins ... degradation processes and increasing the overall protein yield. Researchers ... have visualised the mechanism by which the synthetic ... Menassa worked with a team of researchers from Agriculture ...
... chemical found in blueberry leaves has shown a strong effect ... up a new avenue for treating chronic HCV infections, which ... cirrhosis and liver cancer. Among the areas of ... southern Japan, a trend that led Hiroaki Kataoka and colleagues ...
... is recording its highest-ever winter water temperatures of more than ... to a strengthening of an ocean current originating north of ... remarkable phenomenon a significant extension of the Leeuwin Current ... far north as St Helens. Remote sensing specialists at ...
Cached Biology News:Highest ever winter water temperatures recorded 2
... used to test the crossreactivity of an ... are commonly used as blocking reagents or ... 21 different protein preparations on a nitrocellulose ... species specificity, QC of purified antibodies, selection ...
... HEXALIGHT robot is based on PI's experience ... more than a decade. PI Hexapods were ... and antenna adjustments over wide ranges in ... degrees of freedom with 3 m minimum ...
... Life Sciences can provide custom microplate coating using advanced automated ... variety of plate formats. We can also accommodate virtually any ... of 0.5-320 L):, , ... 96 well microplate, 384 well ...
... full length insert sequencing service for large ... fosmids. Agencourt utilizes unique library construction ... There are several features that allow Agencourt ... rapid turnaround including our patented magnetic bead-based ...
Biology Products: